# From first generation to the next: evolution and research trends in iStent technology

**Authors:** Bryan Chin Hou Ang, Natalie Shi Qi Wong, Bjorn Betzler, Sheng Yang Lim

PMC · DOI: 10.3389/fmed.2025.1724886 · Frontiers in Medicine · 2026-01-23

## TL;DR

The iStent is a minimally invasive glaucoma surgery device that has evolved since 2012 to better reduce eye pressure with few complications.

## Contribution

The paper reviews the evolution and clinical outcomes of successive iStent device generations in glaucoma treatment.

## Key findings

- Long-term iStent use shows durable intraocular pressure and medication reduction with minimal complications.
- iStent effectiveness extends beyond mild-to-moderate open-angle glaucoma, including cases with cataract surgery.
- Combination MIGS with iStent may enhance efficacy without compromising safety.

## Abstract

The iStent series constitutes a range of trabecular bypass minimally invasive glaucoma surgery (MIGS) devices, which offers intraocular pressure (IOP) reduction with favourable safety profiles, in patients with open-angle glaucoma (OAG). Having undergone significant evolution since its initial US FDA-approval in 2012, successive generations address previous limitations, while enhancing IOP-lowering efficacy through device and delivery system design iterations. Longer-term and real-world iStent data demonstrate the durability of IOP- and medication-lowering outcomes with minimal complications, while preliminary studies across a wider spectrum of glaucoma subtypes and severities provide limited evidence of successful outcomes beyond mild-to-moderate OAG, both with and without concomitant cataract surgery. Aqueous humour outflow assessment and novel intra-operative techniques may further facilitate more accurate and effective iStent positioning. Despite typically higher upfront costs, results from both cost-effectiveness and patient-reported outcome studies are encouraging. Combination MIGS with the iStent, leveraging on the multiple mechanisms of actions of various procedures, may provide greater IOP-lowering efficacy without compromising safety. With expanding clinical data and progressive enhancements, iStent technology is likely to remain a key component of the evolving MIGS landscape.

## Linked entities

- **Diseases:** open-angle glaucoma (MONDO:0005338), cataract (MONDO:0005129)

## Full-text entities

- **Diseases:** OAG (MESH:D005902), cataract (MESH:D002386), glaucoma (MESH:D005901)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12875938/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12875938/full.md

## References

99 references — full list in the complete paper: https://tomesphere.com/paper/PMC12875938/full.md

---
Source: https://tomesphere.com/paper/PMC12875938